JP2022526553A5 - - Google Patents

Info

Publication number
JP2022526553A5
JP2022526553A5 JP2021557759A JP2021557759A JP2022526553A5 JP 2022526553 A5 JP2022526553 A5 JP 2022526553A5 JP 2021557759 A JP2021557759 A JP 2021557759A JP 2021557759 A JP2021557759 A JP 2021557759A JP 2022526553 A5 JP2022526553 A5 JP 2022526553A5
Authority
JP
Japan
Prior art keywords
independently selected
substituted
pharmaceutically acceptable
acceptable salt
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526553A (ja
Filing date
Publication date
Priority claimed from GBGB1904375.1A external-priority patent/GB201904375D0/en
Application filed filed Critical
Publication of JP2022526553A publication Critical patent/JP2022526553A/ja
Publication of JP2022526553A5 publication Critical patent/JP2022526553A5/ja
Pending legal-status Critical Current

Links

JP2021557759A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526553A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904375.1 2019-03-29
GBGB1904375.1A GB201904375D0 (en) 2019-03-29 2019-03-29 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2020/058061 WO2020200898A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526553A JP2022526553A (ja) 2022-05-25
JP2022526553A5 true JP2022526553A5 (https=) 2023-04-06

Family

ID=66442789

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557759A Pending JP2022526553A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (14)

Country Link
US (1) US20220296573A1 (https=)
EP (1) EP3947374A1 (https=)
JP (1) JP2022526553A (https=)
KR (1) KR20210143905A (https=)
CN (1) CN113677678A (https=)
AU (1) AU2020252900A1 (https=)
BR (1) BR112021019099A2 (https=)
CA (1) CA3134732A1 (https=)
GB (1) GB201904375D0 (https=)
IL (1) IL286688A (https=)
MX (1) MX2021011574A (https=)
PH (1) PH12021552377A1 (https=)
SG (1) SG11202110643YA (https=)
WO (1) WO2020200898A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
KR20230059584A (ko) 2021-10-26 2023-05-03 주식회사 엘지에너지솔루션 전극 조립체의 제조방법
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1657242A4 (en) * 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine
JPWO2005108399A1 (ja) * 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
RU2675818C2 (ru) * 2013-03-14 2018-12-25 Галапаго Нв Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств
EP3092226B1 (en) * 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
CN108473498B (zh) * 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904374D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2022526553A5 (https=)
JP2022023958A5 (https=)
KR20190053836A (ko) 면역조절제 화합물
JP2021534124A5 (https=)
JP2016518385A5 (https=)
JP2014507455A5 (https=)
JP2012521994A5 (https=)
JP2016515096A5 (https=)
JP2015509535A5 (https=)
JP2014506907A5 (https=)
KR102906376B1 (ko) 항혈소판 약물 및 이의 용도
JPH0314028B2 (https=)
JP2013512277A5 (https=)
JP2011529964A5 (https=)
JP2014500870A5 (https=)
JP2020505440A5 (https=)
JP2013533291A5 (https=)
CA2679232A1 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
JP2013533883A5 (https=)
JP2016532669A5 (https=)
JP2019513745A5 (https=)
CA2143744A1 (en) Diaryl piperazinoacetamide compounds as antimuscarinic agents
JP7200005B2 (ja) 飽和環縮合ジヒドロピリミジノン又はジヒドロトリアジノン化合物及びその医薬用途
JP2022526364A5 (https=)
JP2020511536A5 (https=)